Fate pulls the plug on a cell therapy project after Phase II

Fate Therapeutics ($FATE) is dumping its lead clinical program, moving forward with an early-stage cell therapy the company believes has more commercial promise. The San Diego company is abandoning clinical development of ProHema, a treatment for hematological malignancies that is derived from umbilical cord blood. In a Phase II trial, ProHema demonstrated improved engraftment rates compared to standard hematopoietic cell transplantation, Fate said, but the company is shifting its focus to a preclinical project called ProTmune, which is designed to prevent graft-versus-host disease. Fate is now planning to enroll a Phase I/II clinical trial of ProTmune next year. The company's shares fell about 7% on the news Monday. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.